{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:40:56Z","timestamp":1792528856346,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tips.2026.09.010","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:58Z","timestamp":1792528318000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perianal fistulizing Crohn\u2019s disease: emerging biology, therapeutics, and roadmap for precision treatment"],"prefix":"10.1016","author":[{"given":"Virginia","family":"Solitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bertani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Di Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Giuseppe","family":"Ribaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.09.010_bb0005","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ibd\/izad195","article-title":"Management of perianal fistulizing Crohn\u2019s disease","volume":"30","author":"Singh","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cgh.2025.02.009","article-title":"Defining radiological healing in perianal fistulizing Crohn\u2019s disease: a TOpClass global expert delphi consensus","volume":"24","author":"Anand","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0015","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/ecco-jcc\/jjad214","article-title":"Scoring indices for perianal fistulising Crohn\u2019s disease: a systematic review","volume":"18","author":"Vuyyuru","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0020","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1097\/01.MIB.0000435760.82705.23","article-title":"A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn\u2019s disease-associated fistulae","volume":"19","author":"Frei","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0025","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/medicina60071035","article-title":"Long-term outcome of surgery for perianal Crohn\u2019s fistula","volume":"60","author":"Schaad","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.tips.2026.09.010_bb0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MCG.0000000000001729","article-title":"Rates and predictors of long-term clinical outcomes in patients with perianal Crohn\u2019s disease on biologic therapy","volume":"57","author":"Gubatan","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.tips.2026.09.010_bb0035","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/DCR.0000000000002690","article-title":"Long-term outcomes of perianal fistulas in pediatric Crohn\u2019s disease","volume":"66","author":"Vu","year":"2023","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.tips.2026.09.010_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(26)06754-5","article-title":"1058b Guselkumab for perianal fistulizing Crohn\u2019s disease: week 24 results from the phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study","volume":"170","author":"Peyrin-Biroulet","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.09.010_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2026-339158","article-title":"Ustekinumab for fistulising perianal Crohn\u2019s disease: a randomised placebo-controlled trial from the GETAID","author":"Wils","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.tips.2026.09.010_bb0050","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cgh.2021.09.028","article-title":"Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn\u2019s disease: ENTERPRISE study","volume":"20","author":"Schwartz","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cgh.2024.08.032","article-title":"Efficacy and safety of upadacitinib for perianal fistulizing Crohn\u2019s disease: a post hoc analysis of 3 phase 3 trials","volume":"23","author":"Colombel","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0060","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjae003","article-title":"Efficacy and safety of filgotinib for the treatment of perianal fistulising Crohn\u2019s disease [DIVERGENCE 2]: a phase 2, randomised, placebo-controlled trial","volume":"18","author":"Reinisch","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0065","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/apt.70081","article-title":"The impact of setons on perianal fistula outcomes in patients with Crohn\u2019s disease treated with anti-TNF therapy: a multicentre study","volume":"61","author":"McCurdy","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2026.09.010_bb0070","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.medj.2024.03.021","article-title":"Multimodal single-cell analyses reveal mechanisms of perianal fistula in diverse patients with Crohn\u2019s disease","volume":"5","author":"Levantovsky","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.tips.2026.09.010_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/JCI193413","article-title":"Revealing hyperactivated IFN-\u03b3 pathways in perianal fistulizing Crohn\u2019s disease using single-cell and spatial multi-omics","volume":"135","author":"Cao","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2026.09.010_bb0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41586-025-09744-y","article-title":"Spatial fibroblast niches define Crohn\u2019s fistulae","volume":"649","author":"McGregor","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.09.010_bb0085","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1136\/gutjnl-2025-336246","article-title":"TL1A-activated T cells remodel the rectal mucosa in patients with Crohn\u2019s disease with perianal fistulising disease","volume":"75","author":"Gudi\u00f1o","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.tips.2026.09.010_bb0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ibd\/izae202","article-title":"Microbial and transcriptomic landscape associated with neutrophil extracellular traps in perianal fistulizing Crohn\u2019s disease","volume":"31","author":"Cao","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.gastha.2023.09.002","article-title":"Persistent inflammation of the rectum in perianal fistulizing Crohn\u2019s disease is associated with goblet cell function","volume":"3","author":"Washburn","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.tips.2026.09.010_bb0100","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jcmgh.2022.12.006","article-title":"Dysfunctional extracellular matrix remodeling supports perianal fistulizing Crohn\u2019s disease by a mechanoregulated activation of the epithelial-to-mesenchymal transition","volume":"15","author":"Rizzo","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2468-1253(25)00071-8","article-title":"Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn\u2019s disease: a phase 2a induction trial","volume":"10","author":"Feagan","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0110","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S2468-1253(26)00119-6","article-title":"Efficacy and safety of duvakitug in patients with Crohn\u2019s disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial","volume":"11","author":"Jairath","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.25259\/Cytojournal_148_2024","article-title":"Tumor necrosis factor receptor-associated factor 5 enhances perianal fistulizing Crohn\u2019s disease through epithelial\u2013mesenchymal transition","volume":"21","author":"Sun","year":"2024","journal-title":"Cytojournal"},{"key":"10.1016\/j.tips.2026.09.010_bb0120","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2026.09.010_bb0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/DCR.0000000000002325","article-title":"Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn\u2019s disease: ADMIRE-CD phase 3 randomized controlled trial","volume":"65","author":"Garcia-Olmo","year":"2022","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.tips.2026.09.010_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102473","article-title":"Real-life effectiveness of allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulizing refractory Crohn\u2019s disease","volume":"48","author":"Alonso-Gomez","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.tips.2026.09.010_bb0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/codi.16830","article-title":"Mesenchymal stem cell therapy for Crohn\u2019s perianal fistula\u2014a real-world experience","volume":"26","author":"White","year":"2024","journal-title":"Color. Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0140","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1053\/j.gastro.2025.12.033","article-title":"Darvadstrocel in patients with Crohn\u2019s disease with complex perianal fistulas: the ADMIRE CD II phase 3 randomized trial","volume":"170","author":"Colombel","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.09.010_bb0145","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3389\/fimmu.2018.01849","article-title":"Tumor necrosis factor receptor-associated factor regulation of nuclear factor \u03baB and mitogen-activated protein kinase pathways","volume":"9","author":"Shi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.09.010_bb0150","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41556-025-01713-x","article-title":"Vimentin intermediate filaments as structural and mechanical coordinators of mesenchymal cells","volume":"27","author":"Guo","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tips.2026.09.010_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/ecco-jcc\/jjad118","article-title":"Discontinuation of anti-tumour necrosis factor therapy in patients with perianal fistulizing Crohn\u2019s disease: individual participant data meta-analysis of 309 patients from 12 studies","volume":"18","author":"Bokkel Huinink","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.09.010_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0170","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2026.09.010_bb0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn\u2019s disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"39","author":"Gao","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0180","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","article-title":"Long-term outcome of risankizumab in Crohn\u2019s disease: a real-world GETAID study","volume":"22","author":"Fumery","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0185","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn\u2019s disease: a Belgian multicentric cohort study","volume":"30","author":"Alsoud","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0190","article-title":"Real-world effectiveness of risankizumab in Crohn\u2019s disease: outcome data for an IL-23 inhibitor from the Middle East","volume":"7","author":"Alzaabi","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.tips.2026.09.010_bb0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0200","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.dld.2024.05.009","article-title":"Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn\u2019s disease: the HEAL study from GETECCU","volume":"56","author":"Casanova","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0205","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.dld.2025.08.091","article-title":"Durable clinical and deep remission with ustekinumab in perianal fistulizing Crohn\u2019s disease: a 2-year retrospective real-world cohort study","volume":"57","author":"Chen","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0210","article-title":"The effectiveness of second- and-third-line biologics in perianal Crohn\u2019s disease\u2014a multicenter propensity score-matched study","volume":"19","author":"Shani","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol."},{"key":"10.1016\/j.tips.2026.09.010_bb0220","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2026.09.010_bb0225","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000550543","article-title":"Upadacitinib treatment outcomes in Crohn\u2019s disease: a retrospective analysis of clinical response and perianal fistula resolution","volume":"11","author":"Shiota","year":"2026","journal-title":"Inflamm. Intest. Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0230","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.medj.2024.03.010","article-title":"TL1A inhibition for inflammatory bowel disease treatment: from inflammation to fibrosis","volume":"5","author":"Solitano","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.tips.2026.09.010_bb0235","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2147\/JIR.S458103","article-title":"Mesenchymal stromal cells: new generation treatment of inflammatory bowel disease","volume":"17","author":"Wei","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.tips.2026.09.010_bb0240","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1053\/j.gastro.2026.03.007","article-title":"Interpreting a negative trial in complex perianal Crohn\u2019s disease: the end of allogenic stem cell treatment for fistula patients?","volume":"170","author":"Buskens","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2026.09.010_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjag071","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"20","author":"Yanai","year":"2026","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0250","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ibd\/izad120","article-title":"Safety and monitoring of inflammatory bowel disease advanced therapies","volume":"30","author":"Bhat","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0255","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/ecco-jcc\/jjae089","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: surgical treatment","volume":"18","author":"Adamina","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0260","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/apt.70569","article-title":"Systematic review of published guidelines: recommendations for exams under anaesthesia, seton insertion and timing of seton removal for perianal and rectovaginal fistulising Crohn\u2019s disease","volume":"63","author":"Medawar","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2026.09.010_bb0265","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/ecco-jcc\/jjae035","article-title":"Does combined medical and surgical treatment improve perianal fistula outcomes in patients with Crohn\u2019s disease? A systematic review and meta-analysis","volume":"18","author":"Fung","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0270","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/ecco-jcc\/jjae056","article-title":"TOpCLASS expert consensus classification of perianal fistulising Crohn\u2019s disease: a real-world application in a serial fistula MRI cohort","volume":"18","author":"Schroeder","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0275","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf216","article-title":"Real-world evaluation of MRI fistula volume as a radiological biomarker of disease activity in perianal fistulizing Crohn\u2019s disease","volume":"19","author":"Anand","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0280","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cgh.2024.06.047","article-title":"Perianal fistulizing Crohn\u2019s disease: utilizing the TOpClass classification in clinical practice to provide targeted individualized care","volume":"23","author":"Hanna","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2026.09.010_bb0285","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s10151-026-03376-8","article-title":"Biomarkers in the pathogenesis and diagnosis of Crohn\u2019s perianal fistulas: a systematic review","volume":"30","author":"Silva","year":"2026","journal-title":"Tech. Coloproctol."},{"key":"10.1016\/j.tips.2026.09.010_bb0290","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/ibd\/izaa215","article-title":"Biomarkers of Crohn\u2019s disease to support the development of new therapeutic interventions","volume":"26","author":"Porter","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2025.102551","article-title":"Recent innovations in clinical trial design for inflammatory bowel disease","volume":"84","author":"Sedano","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tips.2026.09.010_bb0300","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/ibd\/izae084","article-title":"Challenges in IBD research 2024: precision medicine","volume":"30","author":"Syed","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2026.09.010_bb0305","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ecco-jcc\/jjad138","article-title":"Race and ethnic representation in Crohn\u2019s disease trials of biologic and small molecule medications: a systematic review and meta-analysis","volume":"18","author":"Pelton","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.tips.2026.09.010_bb0310","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.cgh.2025.11.005","article-title":"Recommendations to standardize the conduct of clinical trials evaluating novel therapies for perianal fistulizing Crohn\u2019s disease","volume":"24","author":"Vuyyuru","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:32:06Z","timestamp":1792528326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726002580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"alternative-id":["S0165614726002580"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.010","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perianal fistulizing Crohn\u2019s disease: emerging biology, therapeutics, and roadmap for precision treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}